Researcher
Benedicte De Winter
- Research Expertise:- Visceral pain - Inflammation - ileus - irritable bowel syndrome - IBS - inflammatory bowel disease - IBD - sepsis - experimental and clinical translational research - medisch vaardighedenonderwijs
- Keywords:VISCERAL PAIN, SEPSIS, IRRITABLE BOWEL SYNDROME, INFLAMMATION, INFLAMMATORY BOWEL DISEASE, Medicine
- Disciplines:Gastro-enterology, Inflammation, Pathophysiology
- Research techniques:- in vivo animal models of IBS, IBD and sepsis - visceromotor response and afferent neuronal activity - motility and sensitivity assays - inflammation measurements - Elisa, flowcytometry - vaardigheden, portfolio, stationsproeven
- Users of research expertise:- research labs - pharmaceutical industry - (bio-, para-) medical schools
Affiliations
- Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Responsible
From1 Oct 2013 → Today - Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Member
From1 Oct 2003 → 30 Sep 2013 - Primary and interdisciplinary care Antwerp (ELIZA) (Research group)
Member
From1 Oct 2003 → 30 Sep 2008
Projects
11 - 20 of 32
- A mucin isoform-based biomarker assay to improve follow-up and treatment of inflammatory bowel diseases (IBD) and gastrointestinal (GI) cancers.From1 Oct 2020 → 30 Sep 2022Funding: IOF - technology concept exploration
- Molecular insights in SARS-CoV-2 pathogenesis and epidemiology.From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Infla-Med: Fundamental and translational research into targets for the treatment of inflammatory diseases.From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- Effect of modulation of the integrity of the intestinal barrier in irritable bowel syndrome: a translational approach.From1 Oct 2018 → 31 Oct 2019Funding: Fund Recuperation Fiscal Exemption
- Drug delivery systems and in vivo efficacy of the serine protease inhibitor UAMC-00050 in a preclinical model for irritable bowel syndrome.From1 Oct 2018 → 30 Sep 2019Funding: IOF - Industrial Research Fund
- Functional characterization of human mast cells and basophils in the pathophysiology of diarrhea-predominant irritable bowel syndrome.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- Therapeutic modulation of the gastrointestinal permeability-inflammation-pain axis.From1 Jan 2018 → 31 Dec 2021Funding: BOF - projects, BOF - Other initiatives
- Innovative imaging techniques to predict treatment outcome in pediatric obstructive sleep apnea.From1 Oct 2017 → 30 Sep 2022Funding: FWO fundamental clinical research fellowship
- TRP channel sensitization as target for treatment of hypersensitivity (TRP-sensation).From1 Jul 2017 → 30 Jun 2021Funding: FWO Strategic Basic Research (SBO)
- Welcome Trail: improving weight control and CO-morbidities in children with obesity via executive function training.From1 Jan 2017 → 31 Dec 2020Funding: FWO Applied Biomedical Research (TBM)
Publications
1 - 10 of 165
- The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease(2024)
Authors: Annelies Van Eyck, Wilhelmus Kwanten, Cédric Peleman, Sanae Makhout, Steven Van Laere, Kim Van Hoorenbeeck, Joris De Man, Benedicte De Winter, Sven Francque, Stijn Verhulst
Pages: 512 - 522 - Novel insights in the clinical evaluation and management of childhood obesity(2024)
Authors: Eline Vermeiren, Stijn Verhulst, Kim Van Hoorenbeeck, Benedicte De Winter, Annelies Van Eyck, Luc Bruyndonckx
Number of pages: 251 - Epidemiological characteristics of a population visiting a patient-centered informative website about irritable bowel syndrome(2023)
Authors: Kathleen Van Malderen, Joris De Man, Benedicte De Winter, Heiko De Schepper
Pages: 17 - 25 - Measuring myeloperoxidase activity as a marker of inflammation in gut tissue samples of mice and rat(2023)
Authors: Nikita Hanning, Joris De Man, Benedicte De Winter
Pages: 1 - 9 - Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes(2023)
Authors: Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus Kwanten, Laura Mortelmans, Cédric Peleman, Shivani Chotkoe, Maarten Spinhoven, Floris Vanhevel, et al.
Pages: 1 - 12 - Self-control training supplementing inpatient multidisciplinary obesity treatment in children and adolescents(2023)
Authors: Tiffany Naets, Eline Vermeiren, Leentje Vervoort, Marijke Ysebaert, Stijn Verhulst, Benedicte De Winter, Luc Bruyndonckx, Ann Tanghe, Ann De Guchtenaere, Sandra Verbeken, et al.
Pages: 1 - 12 - Aberrant mucin expression profiles associate with pediatric inflammatory bowel disease presentation and activity(2023)
Authors: Tom Breugelmans, Wout Arras, Lauren-Emma Boen, Eliah Borms, Lisa Kamperdijk, Joris De Man, Els Van de Vijver, Benedicte De Winter, Nicolette Moes, Annemieke Smet
Pages: 589 - 601 - Exploring the role of transmembrane mucins in intestinal barrier dysfunction in inflammatory bowel diseases(2023)
Authors: Tom Breugelmans, Annemieke Smet, Benedicte De Winter, Heiko De Schepper, Joris De Man
Number of pages: 285 - Risk factors associated with severe RSV infection in infants(2023)
Authors: Kim Stobbelaar, Thomas C. Mangodt, Winke Van der Gucht, Lise Delhaise, Jasmine Andries, Valerie Gille, Cyril Barbezange, Annemieke Smet, Benedicte De Winter, Jozef De Dooy, et al.
Pages: 1 - 11 - Novel insights in bronchopulmonary dysplasia(2023)
Authors: Kristien Vanhaverbeke, Stijn Verhulst, Antonius Mulder, Benedicte De Winter, Kevin Lamote, Kim Van Hoorenbeeck, Annelies Van Eyck
Number of pages: 324
Patents
1 - 9 of 9
- Method for determining the severity and prognosis of rsv infection (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Method for determining the severity and prognosis of RSV infection (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)